Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pyxis Oncology ( (PYXS) ) has shared an update.
On February 2, 2026, Pyxis Oncology implemented a leadership transition in which Lara S. Sullivan, M.D., stepped down as president, chief executive officer and chief medical officer, and board member Thomas Civik was appointed interim chief executive officer and principal executive officer, with his interim role supported by a compensation package that includes salary, bonus eligibility and equity incentives tied in part to successful financing or strategic transactions. Announced publicly in a February 3, 2026 press release, the company emphasized continuity of operations and strategic focus during the CEO search, noting that its existing clinical development team will continue advancing its lead oncology program MICVO through ongoing early-stage trials, underscoring management’s priority to maintain momentum on key clinical milestones and preserve program stability for stakeholders amid the leadership change.
The most recent analyst rating on (PYXS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Pyxis Oncology stock, see the PYXS Stock Forecast page.
Spark’s Take on PYXS Stock
According to Spark, TipRanks’ AI Analyst, PYXS is a Neutral.
The score is held down primarily by weak financial performance (large persistent losses and high cash burn) and a broadly bearish technical setup (below key moving averages with negative MACD). A notable offset is the positive corporate event (strong early clinical data and incremental financing runway), but valuation support is limited given negative earnings and no dividend.
To see Spark’s full report on PYXS stock, click here.
More about Pyxis Oncology
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing next-generation therapeutics for difficult-to-treat cancers. Its lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate targeting extradomain-B of fibronectin in the tumor extracellular matrix, designed to attack solid tumors through multiple mechanisms and currently being evaluated in Phase 1 and Phase 1/2 studies in recurrent/metastatic head and neck squamous cell carcinoma and other solid tumors, both as a monotherapy and in combination with Merck’s KEYTRUDA (pembrolizumab).
Average Trading Volume: 1,298,339
Technical Sentiment Signal: Sell
Current Market Cap: $94.02M
Learn more about PYXS stock on TipRanks’ Stock Analysis page.